Owlstone Medical doubles Cambridge Science Park footprint
Cancer breathalyser inventor Owlstone Medical has almost doubled its footprint at Cambridge Science Park by taking a 10-year lease on a third building.
Owlstone, which has been based at the park since 2008, will start occupying the 15,954 sq ft two-storey Unit 183, in June.
Property consultant Bidwells, sole agent for the deal, refurbished the office building before agreeing the lease.
The facility is located close to Owlstone’s existing 10,037 sq ft and 8,295 sq ft buildings which comprise a mix of office and laboratory space to accommodate the company’s 130 employees.
Owlstone Medical’s innovative Breath Biopsy platform has the potential to revolutionise early detection and precision medicine, with applications in cancer and a wide range of other conditions. The technology enables disease to be detected earlier when treatments are more effective.
Billy Boyle, co-founder and CEO at Owlstone Medical, said: “Owlstone Medical has ambitious growth and expansion plans and by adding the new building to our existing premises on the science park, we can accommodate the team as it grows.
“It also allows for increased capacity in our state-of-the-art laboratories to handle more Breath Biopsy service projects as well as support our ongoing clinical trials.”
Bidwells’ building consultancy team designed, specified and administered a CAT A refurbishment of the unit on behalf of the landlord, including the installation of new suspended ceilings, featuring LED lighting; installation of raised access floors throughout; upgrading the mechanical and electrical Installations and the provision of welfare facilities. The accommodation includes cycle storage, dedicated car parking and landscaped gardens.
Bridget Partridge, surveyor at Bidwells, said: “This deal signifies not only Owlstone Medical’s continued success and ambition but also the company’s satisfaction with its Cambridge Science Park location.
“It’s a further vote of confidence in the Cambridge Science Park and its ongoing investment programme of significant enhancements to the park’s public realm, landscaping and access.”
Owlstone recently raised £11 million to drive the global commercialisation of its platform, enabling the company to bring its lung cancer test to market, extend its early detection pipeline with ongoing trials across multiple cancers, and further grow its existing precision medicine services to the pharmaceutical industry.
Blackwell Consulting represented Owlstone Medical in the deal.